Effect of Different Adjuvants on the Performance of SARS-CoV-2 Vaccines: A Narrative Review of Phase III Trials
Journal of Health, Wellness and Community Research · 23.07.2026 · 4 (14) · 1-10
DOI: 10.61919/mbt5tc22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health, Wellness and Community Research, online erschienen am 23.07.2026. Verfasst von Humna Farooqi und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The rapid development of vaccines against severe acute respiratory syndrome coronavirus 2 introduced diverse technological platforms, antigen designs, dosing schedules, delivery routes, and adjuvant systems. Adjuvants are important components of several inactivated, recombinant protein, protein-subunit, and conjugated vaccines because they can strengthen innate and adaptive immune responses. However, the clinical performance of an adjuvanted vaccine is determined by the complete formulation and cannot be attributed to the adjuvant alone.
Objective
To narratively review the characteristics and reported efficacy of late-phase SARS-CoV-2 vaccines, with particular emphasis on the biological role, clinical context, and apparent performance patterns of their adjuvant systems.
Methods
A structured narrative review was undertaken using literature identified through PubMed, the Cochrane Library, ScienceDirect, Google Scholar, ClinicalTrials.gov, and CenterWatch. Phase III and combined Phase II/III vaccine trials, supporting immunological studies, and relevant publications on SARS-CoV-2 vaccine platforms and adjuvants were considered. Evidence was organized thematically according to vaccine platform, adjuvant system, dosing regimen, trial-level efficacy, infection outcomes, and implementation characteristics. Numerical findings were interpreted descriptively because the included trials differed substantially in populations, circulating variants, endpoints, follow-up periods, baseline risks, and trial settings.
Results
The reviewed vaccines included inactivated whole-virus, adenoviral-vector, recombinant protein, protein-subunit, DNA, conjugated protein, and intranasal live-attenuated platforms. Reported adjuvants included alum, aluminium hydroxide, alumina, AS03, CpG-1018 combined with alum, Advax-SM, and a toll-like receptor 7/8 agonist combined with alum. Trial-reported efficacy ranged from 15.3% to 92.2%. Most vaccine–control comparisons demonstrated lower infection frequencies among vaccinated participants, although marked variation existed across formulations and trial contexts. The evidence did not permit separation of the independent contribution of an adjuvant from that of the antigen, platform, dosage, route, schedule, or epidemiological setting.
Conclusion
Adjuvants contributed to the immunological architecture of several successful SARS-CoV-2 vaccines, but available cross-trial evidence did not establish the independent superiority of any individual adjuvant. Future research should directly compare alternative adjuvant formulations using standardized endpoints, comparable populations, and consistent follow-up periods.
Zitieren
APA
Farooqi, H., Tufail, M., Akbar, A., Shaharyar, S. Z., Iqbal, S., Azhar, F., Nishat, & Shaukat, M. (2026). Effect of Different Adjuvants on the Performance of SARS-CoV-2 Vaccines: A Narrative Review of Phase III Trials. Journal of Health, Wellness and Community Research, 4(14), 1-10. https://doi.org/10.61919/mbt5tc22
Vancouver
Farooqi H, Tufail M, Akbar A, Shaharyar SZ, Iqbal S, Azhar F, et al. Effect of Different Adjuvants on the Performance of SARS-CoV-2 Vaccines: A Narrative Review of Phase III Trials. Journal of Health, Wellness and Community Research. 2026;4(14):1-10. doi:10.61919/mbt5tc22
BibTeX
@article{Farooqi2026,
author = {Farooqi, Humna and Tufail, Meerab and Akbar, Areeha and Shaharyar, Syeda Zahra and Iqbal, Saba and Azhar, Fatima and Nishat and Shaukat, Misbah},
title = {Effect of Different Adjuvants on the Performance of SARS-CoV-2 Vaccines: A Narrative Review of Phase III Trials},
journal = {Journal of Health, Wellness and Community Research},
year = {2026},
volume = {4},
number = {14},
pages = {1--10},
doi = {10.61919/mbt5tc22}
}
EUVIMED